{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:44:10Z","timestamp":1787237050838,"version":"build-2736575974"},"reference-count":20,"publisher":"American Association for Cancer Research (AACR)","issue":"17","funder":[{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["36173\/36228"],"award-info":[{"award-number":["36173\/36228"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","award":["110703"],"award-info":[{"award-number":["110703"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","award":["111091"],"award-info":[{"award-number":["111091"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Italian Foundation for Cancer Research","doi-asserted-by":"publisher","award":["13732"],"award-info":[{"award-number":["13732"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer immunotherapy can result in durable tumor regressions in some patients. However, patients who initially respond often experience tumor progression. Here, we report mechanistic evidence of tumoral immune escape in an exemplary clinical case: a patient with metastatic melanoma who developed disease recurrence following an initial, unequivocal radiologic complete regression after T-cell\u2013based immunotherapy. Functional cytotoxic T-cell responses, including responses to one mutant neoantigen, were amplified effectively with therapy and generated durable immunologic memory. However, these immune responses, including apparently effective surveillance of the tumor mutanome, did not prevent recurrence. Alterations of the MHC class I antigen-processing and presentation machinery (APM) in resistant cancer cells, but not antigen loss or impaired IFN\u03b3 signaling, led to impaired recognition by tumor-specific CD8+ T cells. Our results suggest that future immunotherapy combinations should take into account targeting cancer cells with intact and impaired MHC class I\u2013related APM. Loss of target antigens or impaired IFN\u03b3 signaling does not appear to be mandatory for tumor relapse after a complete radiologic regression. Personalized studies to uncover mechanisms leading to disease recurrence within each individual patient are warranted. Cancer Res; 77(17); 4562\u20136. \u00a92017 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-16-3172","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T20:40:45Z","timestamp":1498596045000},"page":"4562-4566","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFN\u03b3 Signaling"],"prefix":"10.1158","volume":"77","author":[{"given":"Marco","family":"Donia","sequence":"first","affiliation":[{"name":"1Department of Hematology, Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Denmark."},{"name":"2Department of Oncology, Copenhagen University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Harbst","sequence":"additional","affiliation":[{"name":"3Division of Oncology and Pathology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"van Buuren","sequence":"additional","affiliation":[{"name":"4Division of Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Kvistborg","sequence":"additional","affiliation":[{"name":"4Division of Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias F.","family":"Lindberg","sequence":"additional","affiliation":[{"name":"5Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Andersen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Denmark."},{"name":"2Department of Oncology, Copenhagen University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Idorn","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamaila","family":"Munir Ahmad","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Elleb\u00e6k","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Denmark."},{"name":"2Department of Oncology, Copenhagen University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Mueller","sequence":"additional","affiliation":[{"name":"6Institute for Medical Immunology, Martin Luther University, Halle-Wittenberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fagone","sequence":"additional","affiliation":[{"name":"7Department of Bio-medical Sciences, University of Catania, Catania, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[{"name":"7Department of Bio-medical Sciences, University of Catania, Catania, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Libra","sequence":"additional","affiliation":[{"name":"7Department of Bio-medical Sciences, University of Catania, Catania, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lauss","sequence":"additional","affiliation":[{"name":"3Division of Oncology and Pathology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sine Reker","family":"Hadrup","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[{"name":"8Department of Oncology, Aarhus University Hospital, Aarhus, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Hald","family":"Andersen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"thor Straten","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas A.","family":"Nilsson","sequence":"additional","affiliation":[{"name":"4Division of Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton N.","family":"Schumacher","sequence":"additional","affiliation":[{"name":"5Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seliger","sequence":"additional","affiliation":[{"name":"6Institute for Medical Immunology, Martin Luther University, Halle-Wittenberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"J\u00f6nsson","sequence":"additional","affiliation":[{"name":"3Division of Oncology and Pathology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Denmark."},{"name":"2Department of Oncology, Copenhagen University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"2022061706030612600_bib1","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"2022061706030612600_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9504","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006","volume":"34","author":"Schachter","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022061706030612600_bib3","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022061706030612600_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc.2016.2","article-title":"Acquired resistance to immunotherapy and future challenges","volume":"16","author":"Restifo","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2022061706030612600_bib5","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.molonc.2014.07.011","article-title":"Acquired and intrinsic resistance in cancer immunotherapy","volume":"8","author":"Kelderman","year":"2014","journal-title":"Mol Oncol"},{"key":"2022061706030612600_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature18945","article-title":"Neoantigen landscape dynamics during human melanoma\u2013T-cell interactions","volume":"536","author":"Verdegaal","year":"2016","journal-title":"Nature"},{"key":"2022061706030612600_bib7","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1158\/0008-5472.CAN-16-0008","article-title":"Melanoma lesions independently acquire t-cell resistance during metastatic latency","volume":"76","author":"Zhao","year":"2016","journal-title":"Cancer Res"},{"key":"2022061706030612600_bib8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061706030612600_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1479-5876-10-169","article-title":"Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients","volume":"10","author":"Ellebaek","year":"2012","journal-title":"J Transl Med"},{"key":"2022061706030612600_bib10","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1158\/0008-5472.CAN-14-2956","article-title":"Aberrant expression of MHC Class II in melanoma attracts inflammatory tumor specific CD4+ T cells which dampen CD8+ T cell antitumor reactivity","volume":"75","author":"Donia","year":"2015","journal-title":"Cancer Res"},{"key":"2022061706030612600_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/jid.2012.336","article-title":"Methods to improve adoptive T-cell therapy for melanoma: IFN-\u03b3 enhances anticancer responses of cell products for infusion","volume":"133","author":"Donia","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2022061706030612600_bib12","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-11-2614","article-title":"Dissection of T-cell antigen specificity in human melanoma","volume":"72","author":"Andersen","year":"2012","journal-title":"Cancer Res"},{"key":"2022061706030612600_bib13","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"van Rooij","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022061706030612600_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-3083.2011.02640.x","article-title":"Characterization and comparison of \u201cStandard\u201d and \u201cYoung\u201d tumor infiltrating lymphocytes for adoptive cell therapy at a danish translational research institution","volume":"75","author":"Donia","year":"2011","journal-title":"Scand J Immunol"},{"key":"2022061706030612600_bib15","doi-asserted-by":"crossref","first-page":"574695","DOI":"10.1155\/2011\/574695","article-title":"Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application","volume":"2011","author":"Junker","year":"2011","journal-title":"J Skin Cancer"},{"key":"2022061706030612600_bib16","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1158\/1078-0432.CCR-10-2114","article-title":"Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines","volume":"17","author":"Respa","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022061706030612600_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ijc.28338","article-title":"Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma","volume":"134","author":"Del Campo","year":"2014","journal-title":"Int J Cancer"},{"key":"2022061706030612600_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-016-0127-z","article-title":"Targetless T cells in cancer immunotherapy","volume":"4","author":"Thor Straten","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2022061706030612600_bib19","first-page":"1601","article-title":"The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible \u201chard\u201d lesions","volume-title":"Cancer Immunol Immunother","author":"Garrido","year":"2010"},{"key":"2022061706030612600_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ijc.26471","article-title":"Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes","volume":"131","author":"Carretero","year":"2012","journal-title":"Int J Cancer"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/17\/4562\/2753897\/4562.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/17\/4562\/2753897\/4562.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T12:56:42Z","timestamp":1655470602000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/77\/17\/4562\/622721\/Acquired-Immune-Resistance-Follows-Complete-Tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":20,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2017,8,31]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-16-3172","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22414446.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6508980","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414446","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414449.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414449","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6508980.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}